Far from the big hubs, Apel­lis is steer­ing its ri­val to Alex­ion's Soliris in­to a PhI­II pro­gram

A Ken­tucky biotech says they’re lay­ing the foun­da­tion for a piv­otal pro­gram for their C3 in­hi­bi­tion ther­a­py, which ex­ecs be­lieve can re­place Soliris in treat­ing PNH.

Louisville-based Apel­lis has been mak­ing progress on its lead drug far away from the spot­light that con­cen­trates at­ten­tion on the big biotech hubs. But it’s been well fund­ed, with a $47 mil­lion D round that dropped ear­ly last year af­ter they gave up on an IPO in chilly mar­ket wa­ters. And the com­pa­ny says they’ve been nail­ing down hard hu­man ev­i­dence that by mov­ing up­stream from C5 in­hi­bi­tion, where Soliris hits, they can do a bet­ter job in con­trol­ling ane­mia and trans­fu­sion de­pen­dence among pa­tients with this ex­treme­ly rare con­di­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.